MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis

Abstract Background Accumulating studies have evaluated the association between MAP3K1 polymorphisms and cancer prognosis. However, the results of these studies are conflicting. Given the potential impact of MAP3K1 rs889312 SNP on the prognosis of various cancers, this meta‐analysis was performed to...

Full description

Bibliographic Details
Main Authors: Md. Abdul Aziz, Mohammad Safiqul Islam
Format: Article
Language:English
Published: Wiley 2023-01-01
Series:Cancer Reports
Subjects:
Online Access:https://doi.org/10.1002/cnr2.1773
_version_ 1811169290365173760
author Md. Abdul Aziz
Mohammad Safiqul Islam
author_facet Md. Abdul Aziz
Mohammad Safiqul Islam
author_sort Md. Abdul Aziz
collection DOAJ
description Abstract Background Accumulating studies have evaluated the association between MAP3K1 polymorphisms and cancer prognosis. However, the results of these studies are conflicting. Given the potential impact of MAP3K1 rs889312 SNP on the prognosis of various cancers, this meta‐analysis was performed to obtain solid and credible evidence. Methods and Materials This study was performed according to the PRISMA 2020 statement. A comprehensive article search was conducted to find and select articles from multiple databases, including PubMed, Google Scholar, Web of Science, EMBASE and the Cochrane Library, published up to 15th September 2022. The data analysis was performed with Review Manager v5.2. Pooled HR with its 95% CI and p‐value was calculated where HR >1 suggests worse/poor survival and HR <1 suggests better survival of cancer patients. Results A total of five articles comprising 24 439 patients were included for both qualitative and quantitative data synthesis. It was found that only the dominant genetic model (AC + CC vs. AA) showed a statistically significant poor overall survival for MAP3K1 rs889312 polymorphism (HR = 1.25, 95% CI = 1.06–1.47, p = .01). In addition, publication bias analysis by the Egger's test and the Begg‐Mazumdar test reported no significant bias in the analysis of overall survival (p > .05). Conclusions The present study concludes that MAP3K1 gene rs889312 polymorphism plays a prognostic role in the survival of cancer patients. However, future research is recommended that will analyze more MAP3K SNPs along with rs889312, which may reveal more credible outcomes in terms of cancer prognosis.
first_indexed 2024-04-10T16:39:54Z
format Article
id doaj.art-5696230a72e14297ac5a316e7362d383
institution Directory Open Access Journal
issn 2573-8348
language English
last_indexed 2024-04-10T16:39:54Z
publishDate 2023-01-01
publisher Wiley
record_format Article
series Cancer Reports
spelling doaj.art-5696230a72e14297ac5a316e7362d3832023-02-08T07:31:30ZengWileyCancer Reports2573-83482023-01-0161n/an/a10.1002/cnr2.1773MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysisMd. Abdul Aziz0Mohammad Safiqul Islam1Department of Pharmacy, Faculty of Pharmacy and Health Sciences State University of Bangladesh Dhaka BangladeshDepartment of Pharmacy, Faculty of Science Noakhali Science and Technology University Noakhali BangladeshAbstract Background Accumulating studies have evaluated the association between MAP3K1 polymorphisms and cancer prognosis. However, the results of these studies are conflicting. Given the potential impact of MAP3K1 rs889312 SNP on the prognosis of various cancers, this meta‐analysis was performed to obtain solid and credible evidence. Methods and Materials This study was performed according to the PRISMA 2020 statement. A comprehensive article search was conducted to find and select articles from multiple databases, including PubMed, Google Scholar, Web of Science, EMBASE and the Cochrane Library, published up to 15th September 2022. The data analysis was performed with Review Manager v5.2. Pooled HR with its 95% CI and p‐value was calculated where HR >1 suggests worse/poor survival and HR <1 suggests better survival of cancer patients. Results A total of five articles comprising 24 439 patients were included for both qualitative and quantitative data synthesis. It was found that only the dominant genetic model (AC + CC vs. AA) showed a statistically significant poor overall survival for MAP3K1 rs889312 polymorphism (HR = 1.25, 95% CI = 1.06–1.47, p = .01). In addition, publication bias analysis by the Egger's test and the Begg‐Mazumdar test reported no significant bias in the analysis of overall survival (p > .05). Conclusions The present study concludes that MAP3K1 gene rs889312 polymorphism plays a prognostic role in the survival of cancer patients. However, future research is recommended that will analyze more MAP3K SNPs along with rs889312, which may reveal more credible outcomes in terms of cancer prognosis.https://doi.org/10.1002/cnr2.1773cancerMAP3K1meta‐analysispolymorphismprognosissurvival
spellingShingle Md. Abdul Aziz
Mohammad Safiqul Islam
MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
Cancer Reports
cancer
MAP3K1
meta‐analysis
polymorphism
prognosis
survival
title MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
title_full MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
title_fullStr MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
title_full_unstemmed MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
title_short MAP3K1 rs889312 polymorphism and cancer prognosis: A systematic review and meta‐analysis
title_sort map3k1 rs889312 polymorphism and cancer prognosis a systematic review and meta analysis
topic cancer
MAP3K1
meta‐analysis
polymorphism
prognosis
survival
url https://doi.org/10.1002/cnr2.1773
work_keys_str_mv AT mdabdulaziz map3k1rs889312polymorphismandcancerprognosisasystematicreviewandmetaanalysis
AT mohammadsafiqulislam map3k1rs889312polymorphismandcancerprognosisasystematicreviewandmetaanalysis